To the best of our knowledge, this is the first report to incorporate CA19–9 and CEA together to evaluate whether the combination of these two biomarkers could present a predictive value for survival outcome of ESCC patients. This evidence concerns the gene CEACAM5 and esophageal squamous cell carcinoma.